{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T15:35:13Z","timestamp":1726414513768},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T00:00:00Z","timestamp":1362182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11883-013-0318-8","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T00:39:27Z","timestamp":1362184767000},"source":"Crossref","is-referenced-by-count":3,"title":["Acute Coronary Syndromes: Advances in Antithrombotics"],"prefix":"10.1007","volume":"15","author":[{"given":"Nilusha","family":"Gukathasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,2]]},"reference":[{"issue":"22","key":"318_CR1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"FG Kushner","year":"2009","unstructured":"Kushner FG et al. Focused Updates: ACC\/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC\/AHA\/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271\u2013306.","journal-title":"Circulation"},{"issue":"13","key":"318_CR2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Yusuf S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519\u201330.","journal-title":"JAMA"},{"issue":"4","key":"318_CR3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL et al. Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18\u2013209.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"318_CR4","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.2967\/jnumed.109.069633","volume":"51","author":"P Libby","year":"2010","unstructured":"Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med. 2010;51 Suppl 1:33S\u20137.","journal-title":"J Nucl Med"},{"issue":"25","key":"318_CR5","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","volume":"111","author":"P Libby","year":"2005","unstructured":"Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481\u20138.","journal-title":"Circulation"},{"issue":"12","key":"318_CR6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1586\/erc.12.157","volume":"10","author":"G Cimmino","year":"2012","unstructured":"Cimmino G et al. The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations. Expert Rev Cardiovasc Ther. 2012;10(12):1533\u201343.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"9281","key":"318_CR7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527\u201333.","journal-title":"Lancet"},{"issue":"2","key":"318_CR8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","volume":"50","author":"NA Farid","year":"2010","unstructured":"Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126\u201342.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"318_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1160\/TH11-03-0167","volume":"106","author":"PA Gurbel","year":"2011","unstructured":"Gurbel PA, Tantry US. Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. Thromb Haemost. 2011;106(2):265\u201371.","journal-title":"Thromb Haemost"},{"issue":"2","key":"318_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","volume":"45","author":"VL Serebruany","year":"2005","unstructured":"Serebruany VL et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"318_CR11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14656566.2011.550573","volume":"12","author":"MA Giorgi","year":"2011","unstructured":"\u2022 Giorgi MA et al. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother. 2011;12(8):1285\u201395. This publication discusses the pharmacokinetics and dynamics of prasugrel, clopidogrel, and ticagrelor.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"318_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin L et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21\u201330.","journal-title":"Eur Heart J"},{"issue":"20","key":"318_CR13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"9665","key":"318_CR14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723\u201331.","journal-title":"Lancet"},{"key":"318_CR15","unstructured":"Effient [package insert], 2012: Indianapolis, IN: Eli Lilly & Co."},{"issue":"11","key":"318_CR16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"\u2022\u2022 Wallentin L et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. This trial assessed the safety and efficacy of ticagrelor vs. clopidogrel and showed a decrease with ticagrelor in the primary efficacy endpoint without an increase in the primary safety endpoint.","journal-title":"N Engl J Med"},{"issue":"9711","key":"318_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","volume":"375","author":"CP Cannon","year":"2010","unstructured":"Cannon CP et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283\u201393.","journal-title":"Lancet"},{"issue":"11","key":"318_CR18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056\u201367.","journal-title":"Circulation"},{"issue":"6","key":"318_CR19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","volume":"57","author":"C Held","year":"2011","unstructured":"Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"318_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"318_CR21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"DA Morrow","year":"2009","unstructured":"Morrow DA et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158(3):335\u201341. e3.","journal-title":"Am Heart J"},{"issue":"15","key":"318_CR22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404\u201313.","journal-title":"N Engl J Med"},{"issue":"22","key":"318_CR23","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781\u20139.","journal-title":"Eur Heart J"},{"issue":"9683","key":"318_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"issue":"22","key":"318_CR25","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877\u201385.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"318_CR26","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","volume":"15","author":"J Stangier","year":"2009","unstructured":"Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15 Suppl 1:9S\u201316.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9591","key":"318_CR27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949\u201356.","journal-title":"Lancet"},{"issue":"11","key":"318_CR28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Thromb Haemost: JTH. 2007;5(11):2178\u201385.","journal-title":"Thromb Haemost: JTH"},{"issue":"12","key":"318_CR29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"3","key":"318_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn E et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"318_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"318_CR32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos Biol Fate Chem. 2009;37(1):74\u201381.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"318_CR33","first-page":"274","volume":"96","author":"JI Weitz","year":"2006","unstructured":"Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006;96(3):274\u201384.","journal-title":"Thromb Haemost"},{"key":"318_CR34","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Komocsi A et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(20):1537\u201345. This is a meta-analysis from 7 heterogeneous trials, showed novel oral anticoagulant (NOAC) therapy was associated with an astonishing 3-fold increased risk for major bleeding. There was however no difference in the net clinical benefit outcome.","DOI":"10.1001\/archinternmed.2012.4026"},{"key":"318_CR35","doi-asserted-by":"crossref","unstructured":"Spyropoulos AC et al. Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm? J Thromb Haemost. 2012;10(12):2621\u20134.","DOI":"10.1111\/jth.12005"},{"key":"318_CR36","unstructured":"Secondary prevention of small subcortical strokes trial: NINDS stops treatment with combination antiplatelet therapy (Clopidogrel plus Aspirin) due to higher risk of major hemorrhage and death. http:\/\/www.nlm.nih.gov\/databases\/alerts\/2011_ninds_stroke.html . Accessed 28 Dec 2012."},{"key":"318_CR37","doi-asserted-by":"crossref","unstructured":"\u2022 Hernandez AV. No place for novel oral anticoagulants in current treatment of acute coronary syndromes: comment on \"use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome\". Arch Intern Med. 2012;172(20):1546\u201347. A great commentary on a meta-analysis of 7 trials by Komocsi et al discussing the dilemmas with the use of NOAC in ACS.","DOI":"10.1001\/2013.jamainternmed.293"},{"issue":"4","key":"318_CR38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ahj.2007.12.034","volume":"155","author":"P Gladding","year":"2008","unstructured":"Gladding P et al. Antiplatelet drug nonresponsiveness. Am Heart J. 2008;155(4):591\u20139.","journal-title":"Am Heart J"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-013-0318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-013-0318-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-013-0318-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T06:14:49Z","timestamp":1562739289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-013-0318-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,2]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s11883-013-0318-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"type":"print","value":"1523-3804"},{"type":"electronic","value":"1534-6242"}],"subject":[],"published":{"date-parts":[[2013,3,2]]},"article-number":"318"}}